Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia

Nobuaki Mori; Mitsuya Katayama; Shigenari Nukaga

Journal of Microbiology, Immunology and Infection (Feb 2021)

Triple therapy with hydroxychloroquine, azithromycin, and ciclesonide for COVID-19 pneumonia

Nobuaki Mori,
Mitsuya Katayama,
Shigenari Nukaga

Affiliations

Nobuaki Mori: Department of General Internal Medicine and Infectious Diseases, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan; Corresponding author. Department of General Internal Medicine and Infectious Diseases, National Hospital Organization, Tokyo Medical Center, 2-5-1 Higashigaoka, Meguro-ku, Tokyo 152-8902, Japan. Fax: +81 3 3412-9811.
Mitsuya Katayama: Department of General Internal Medicine and Infectious Diseases, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan
Shigenari Nukaga: Department of Respiratory Medicine, National Hospital Organization, Tokyo Medical Center, Tokyo, Japan

Journal volume & issue: Vol. 54, no. 1
pp. 109 – 112

Abstract

Read online

No specific therapy is available for COVID-19. We report the effectiveness and adverse effects of triple therapy with hydroxychloroquine, azithromycin, and ciclesonide in patients with COVID-19 pneumonia. The clinical condition of the patients improved within 5 days in response to the therapy.

Published in Journal of Microbiology, Immunology and Infection

ISSN: 1684-1182 (Print)
Publisher: Elsevier
Country of publisher: Hong Kong
LCC subjects: Science: Microbiology
Website: https://www.sciencedirect.com/journal/journal-of-microbiology-immunology-and-infection

About the journal

Abstract

Keywords